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To the editor:
Treatment outcome in infant acute lymphoblastic leukemia
We read with interest the paper of Do¨rdelmann et al1 on prednisone
(PDN) response as the strongest predictor value of outcome in
infant acute lymphoblastic leukemia (ALL).
Between June 1989 and November 1998, 60 (3.1%) infants,
among 1963 children less than 18 years of age, were registered
and treated according to the Children Leukemia Coopera-
tive Group-European Organization for Research and Treat-
ment of Cancer (CLCG-EORTC) protocol 58881. Patients were
stratified according to the same risk factor (RF) as defined in
Do¨rdelmann et als paper:1 RF , 0.8 assigned them to the
low risk (LR) group, and RF $ 0.8 to the standard risk (SR)
group. Patients with prednisolone poor response (PPR), with
t(9;22) or t(4;11) and/or not in remission (marrow blasts
, 5%) on day 35 were assigned to the very high risk group
(VHR).
Protocol CLCG-EORTC 58881 was very similar to the protocol
ALL-BFM86 except for the following points: (1) prednisolone
instead of prednisone and additional It MTX were used during
induction, (2) protocol II was given to all LR and SR patients, (3)
VHR patients, after induction, received 9 blocks of multi-
agents chemotherapy, followed by conventional maintenance for 1
year. In addition, a proportion of the patients were randomized to
receive the following: (1) either Erwinia or E coli asparaginase
(all ALL patients in induction and consolidation) (2) HD MTX
versus Ara-C plus HD MTX during interval therapy (standard risk
patients) (3) pulses of 6 MP IV during maintenance therapy (all
patients). In contrast with Berlin-Frankfurt-Mu¨nster (BFM)
protocol, no patient received prophylactic or therapeutic cranial
irradiation.
Figure 1. Probability of EFS for infants with ALL, according to
white blood cell (WBC) counts at diagnosis.
Outcome according to presenting features in infant ALL treated
with EORTC protocol #58881
n EFS (%)* HR† P value
Age
Less than 6 mo 34 30 1.7 .13
At least 6 mo 26 56 1
WBC (3103/µL)
Lower than 25 9 80 1
Lower than 100 16 57 4.1 ,.001
At least 100 35 26 11.6
Prednisolone response
Good (,1000/µL) 38 48 1 .02
Poor ($1000/µL) 21 29 2.1
VHR feature
No 19 64 1 .01
Yes 41 27 2.8
Immunophenotype
CD102 39 29 3.7 .02
CD101 11 79 1
CD341 18 15 2.3 .03
CD342 21 56 1
Cytogenetics
T(4;11) Yes 26 23 2.5 .01
No 23 63 1
*Event free survival rate at 4 years.
†Hazard ratio completed via the logrank O/E ratio method.
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The overall event free survival (EFS) rate at 4 years in the 60
ALL infants treated with the same protocol was 41%. Univariate
analysis of prognostic factors is given in the Table. Age below 6
months had no significant influence on EFS, but white blood cell
(WBC) counts of at least 100 3 103/µL, PPR, presence of very high
risk features, immunophenotype (CD102 or CD341) had a
significative negative influence on EFS. The leucocyte count had
the most important impact. The EFS of infants with initial
leucocyte count lower than 100 3 103/µL was 65%, which is
comparable to that of older children with initial leucocyte count
between 10 and 100 3 103µL (Figure 1).
In contrast with the ALL-BFM results, the EFS of the 17 PPR
infants with CD102 ALL was 29% (Figure 2), whereas in the
Germany study, none of these infants survived. The difference
between the 2 studies might be treatment-related.
Nevertheless, the overall results are similar with a global EFS of
41%. Of note is that the proportion of infants with CD101 and
steroid good response (PGR) respectively was higher in the BFM
study than in the EORTC 58881 trial: 40% versus 22% for CD101
and 74% versus 64% for PGR. Probably, the percentage of VHR
patients is higher in the EORTC series, as the proportion of PPR
was higher, due to the late administration of the It MTX.2
The number of patients was small in both studies (although
twice as high in the BFM study), and conclusions with regard to the
relation weight of different prognostic features should not be
accepted without qualification. Results of the ongoing international
protocol Interfant 99 will be essential to a refined ranking of the
most important prognostic factors and to further progress in the
treatment of this high-risk group.3-6
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Response:
Early response in infant ALL determines prognosis
We are pleased that our study on prognostic factors in infant acute
lymphoblastic leukemia (ALL) during BFM trials1 provoked some
discussion as indicated by Ferster et al’s letter. We think their data
may give some important additional information regarding the
prognostic value of certain clinical and biologic features in infant
ALL. But in our opinion, their results are neither new nor
inconsistent with our results. They also do not substantially
question the findings and conclusions of our study.
In contrast to Ferster et al’s statement, we think that the EORTC
used both different treatment stratification and different treatment
for a substantial proportion of infants. Because antileukemic
treatment itself is a well-known prognostic factor, this may
significantly influence the prognostic value of clinical or biologic
features.2 On the one hand, patients treated under the CLCG-
EORTC protocol 58881 were stratified according to the same risk
features, namely, tumor cell burden (BFM risk factor) and predni-
sone response. But in contrast to BFM, the translocation t(4;11)
qualified for treatment in the highest-risk group (VHR in EORTC),
and this may explain the much higher percentage of VHR patients
in the EORTC series as compared to our study also (68% vs 26%).
Figure 2. Probability of EFS for infants with ALL presenting
poor prednisolone response (PPR), according to their CD10
expression.
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